Investigator-Sponsored Protocol - Continued Use of Ibalizumab
Status:
Completed
Trial end date:
2016-12-15
Target enrollment:
Participant gender:
Summary
This protocol serves to extend the successful treatment for HIV positive patients beyond the
endpoints provided by the Phase 2b TaiMed Biologics-sponsored protocol TMB202 (entitled "A
Phase 2b Randomized, Double-Blinded, 48-Week, Multicenter, Dose-Response Study of Ibalizumab
Plus an Optimized Background Regimen in Treatment-Experienced Patients Infected with HIV-1
(Amended to 24 Week Study)"), for 24 weeks. Ibalizumab may be administered beyond 24 weeks
under this protocol as supply permits and patients continue to demonstrate virologic
response.